

## CONTENTS

Section	Description	Pg. No.
Contents		I-IX
List of Tables		X-XIV
List of Figures		XV-XVIII
Abbreviations		XIX-XX
<b>Chapter 1: Introduction</b>		<b>1-12</b>
1.1	Dementia	1
1.2	Causes	2
1.3	Treatment options	2
1.3.1	Psychotherapy	2
1.3.2	Environmental modifications	2
1.3.3	Medication	3
1.4	Vinpocetine (VPN)	4
1.4.1	Problems associated with VPN oral medication	4
1.5	Noocept (NPT)	5
1.5.1	Problems associated with NPT oral medication	5
1.6	Transdermal route for drug delivery	5
1.6.1	Overcoming the Stratum corneum barrier	6
1.6.2	Microneedle based skin microporation	6
1.6.3	Dissolving microneedles	7
1.6.4	Nanocarriers as drug delivery vehicles	7
1.6.4.1	Polymeric nanoparticles (PNP)	7
1.6.4.2	Ultradeformable liposomes (UDL)	8
1.6.5	Nanocarriers loaded Microneedle patches	8
1.7	Aims of the study	8
1.8	Plan of work	9
<b>Chapter 2: Literature Review</b>		<b>13-46</b>
2.1	Dementia	13
2.1.1	Prevalence	14
2.1.2	Signs and symptoms	15
2.1.3	Common types of dementia	15
2.1.4	Treatment and care	16
2.2	Vinpocetine (VPN)	17
2.2.1	Vinpocetine Profile	17
2.2.2.	Problems associated with VPN oral medication	21
2.3	Noocept (NPT)	24

<b>Section</b>	<b>Description</b>	<b>Pg. No.</b>
2.3.1	Noopept Profile	24
2.3.2	Problems associated with NPT oral medication	25
2.4	Transdermal route for drug delivery	26
2.4.1	Transdermal route	26
2.4.2	Breaching the Stratum corneum barrier	27
2.4.3	Microneedle based transdermal delivery	29
2.5	Nanocarriers as drug delivery vehicles	30
2.5.1	Polymeric nanoparticles (PNP)	30
2.5.2	Ultradeformable liposomes (UDL)	30
2.5.3	Nanocarriers loaded Microneedle patches	32
2.6	Quality by design	34
2.6.1	Defining quality target product profile (QTPP)	34
2.6.2	Product designing	34
2.6.3	Process designing	34
2.6.4	Establishing CQA, CMA and CPP	35
2.6.5	Controlling the manufacturing process	37
<b>Chapter 3: Analytical Techniques</b>		<b>47-72</b>
3.1.	Introduction	47
3.2.	Materials	48
3.3.	Equipments	49
3.3.1.	UV Spectrophotometer	49
3.3.2.	High performance liquid chromatographic (HPLC) system	49
3.4.	Reagents & Solutions	49
3.4.1.	Filtered double distilled water	49
3.4.2.	Ammonium acetate solution (1.54 %w/w)	49
3.4.3.	Mobile phase for VPN estimation by HPLC	50
3.4.4.	Mobile phase for NPT estimation by HPLC	50
3.5.	Methods	50
3.5.1.	VPN estimation by UV Spectrophotometry	50
3.5.2.	Validation of UV Spectrophotometric methods for VPN	51
3.5.3.	VPN estimation by HPLC method	53
3.5.4.	Validation of HPLC method for VPN	55
3.5.5.	NPT estimation by HPLC methods	55
3.5.6.	Validation of HPLC methods for NPT	57
3.6.	Results & Discussion	57
3.6.1.	VPN estimation by UV spectrophotometry	57
3.6.2.	Validation of UV spectrophotometric methods for VPN	58

<b>Section</b>	<b>Description</b>	<b>Pg. No.</b>
3.6.3.	VPN estimation by HPLC method	62
3.6.4.	Validation of HPLC method for VPN	63
3.6.5.	NPT estimation by HPLC methods	65
3.6.6.	Validation of HPLC methods for NPT	66
3.7.	Conclusion	69
<b>Chapter 4: Preformulation Studies</b>		<b>73-84</b>
4.1.	Introduction	73
4.2.	Materials & Methods	74
4.2.1.	Materials	74
4.2.2.	Authentication of Vinpocetine	74
4.2.2.1.	Melting point determination	74
4.2.2.2.	UV absorption spectrum	74
4.2.2.3.	Fourier transform Infrared (FT-IR) spectrum	75
4.2.2.4.	Differential scanning calorimetry (DSC)	75
4.2.3.	Authentication of Noopept	75
4.2.3.1.	Melting point determination	76
4.2.3.2.	UV absorption spectrum	76
4.2.3.3.	Fourier transform Infrared (FT-IR) spectrum	76
4.2.3.4.	Differential scanning calorimetry (DSC)	77
4.2.4.	Drug-excipients compatibility testing	77
4.3.	Results & discussion	78
4.3.1.	Vinpocetine authentication	78
4.3.1.1.	Melting point determination	78
4.3.1.2.	UV absorption spectrum	78
4.3.1.3.	Fourier transform Infrared (FT-IR) spectrum	78
4.3.1.4.	Differential scanning calorimetry (DSC)	79
4.3.2.	Noopept authentication	80
4.3.2.1.	Melting point determination	80
4.3.2.2.	UV absorption spectrum	80
4.3.2.3.	Fourier transform Infrared (FT-IR) spectrum	81
4.3.2.4.	Differential scanning calorimetry (DSC)	82
4.3.3.	Drug-excipients compatibility testing	82
<b>Chapter 5A: Formulation Development: Ultradeformable Liposomes of Vinpocetine</b>		<b>85-112</b>
5A.1.	Introduction	85
5A.2.	Materials & Methods	86
5A.2.1	Materials	86

<b>Section</b>	<b>Description</b>	<b>Pg. No.</b>
5A.2.2	Preparation of Vinpocetine loaded ultradeformable liposomes (VPN UDL)	86
5A.2.2.1	Establishing Quality target product profile and Critical Quality Attributes	86
5A.2.2.2	Identification of Independent variables (factors) and qualitative risk assessment	87
5A.2.2.3	Quantitative risk assessment: Screening design	87
5A.2.2.4	Formulation optimization by combined D-optimal response surface design	88
5A.2.3	<i>In vitro</i> characterization of optimized VPN UDL	88
5A.2.3.1	Shape and surface morphology	88
5A.2.3.2	Zeta potential	89
5A.2.3.3	<i>In vitro</i> drug release study	89
5A.3.	Results & Discussion	90
5A.3.1	Preparation and optimization of VPN loaded UDL	90
5A.3.1.1	Establishing QTPP and CQA	90
5A.3.1.2	Identification and qualitative assessment of Independent variables (factors)	91
5A.3.1.3	Qualitative risk assessment	91
5A.3.1.4	Quantitative risk assessment: Screening Design	93
5A.3.1.5	Formulation optimization by combined D-optimal response surface design	96
5A.3.2	<i>In vitro</i> characterization of optimized VPN-UDL	107
5A.3.2.1	Shape and surface morphology	107
5A.3.2.2	Zeta potential	110
5A.3.2.3	<i>In vitro</i> drug release study	110
<b>Chapter 5B: Formulation Development: Ultradeformable Liposomes of Noopept</b>		<b>113-142</b>
5B.1.	Introduction	113
5B.2.	Materials & methods	114
5B.2.1	Materials	114
5B.2.2	Preparation of Noopept loaded ultradeformable liposomes (NPT-UDL)	114
5B.2.2.1	Establishing Quality target product profile and Critical Quality Attributes	115
5B.2.2.2	Identification of Independent variables (factors) and qualitative risk assessment	115
5B.2.2.3	Quantitative risk assessment: Screening design	115
5B.2.2.4	Formulation optimization by combined D-optimal response surface design	116
5B.2.3	<i>In vitro</i> characterization of optimized NPT-UDL	117
5B.2.3.1	Shape and surface morphology	117

<b>Section</b>	<b>Description</b>	<b>Pg. No.</b>
5B.2.3.2	Zeta potential	117
5B.2.3.3	In-vitro drug release study	117
5B.3.	Results & discussion	118
5B.3.1	Preparation and optimization of NPT loaded ultradeformable liposomes	118
5B.3.1.1	Establishing QTPP and CQA	118
5B.3.1.2	Identification and qualitative assessment of Independent variables (factors)	119
5B.3.1.3	Qualitative risk assessment	120
5B.3.1.4	Quantitative risk assessment: Screening Design	122
5B.3.1.5	Formulation optimization by combined D-optimal response surface design	124
5B.3.2	In vitro characterization of optimized NPT-UDL	138
5B.3.2.1	Shape and surface morphology	138
5B.3.2.2	Zeta potential	141
5B.3.2.3	<i>In vitro</i> drug release study	141
<b>Chapter 6A: Formulation Development: Polymeric Nanoparticles of Vinpocetine</b>		<b>143-172</b>
6A.1.	Introduction	143
6A.2.	Materials & methods	143
6A.2.1	Materials	143
6A.2.2	Preparation of Vinpocetine loaded polymeric nanoparticles (VPN-PNP)	144
6A.2.2.1	Establishing Quality target product profile (QTPP) and Critical Quality Attributes (CQA)	144
6A.2.2.2	Identification of Independent variables (factors) and qualitative risk assessment	144
6A.2.2.3	Quantitative risk assessment: Screening design	145
6A.2.2.4	Formulation optimization by Box Behnken response surface design	146
6A.2.3	In-vitro characterization of optimized VPN-PNP	146
6A.2.3.1	Shape and surface morphology	146
6A.2.3.2	Zeta potential	147
6A.2.3.3	In-vitro drug release study	147
6A.3.	Results & discussion	148
6A.3.1	Preparation and optimization of VPN loaded polymeric nanoparticles	148
6A.3.1.1	Establishing QTPP and CQA	148
6A.3.1.2	Identification and qualitative assessment of Independent variables (factors)	149
6A.3.1.3	Qualitative risk assessment	149
6A.3.1.4	Quantitative risk assessment: Screening Design	151

<b>Section</b>	<b>Description</b>	<b>Pg. No.</b>
6A.3.1.5	Formulation optimization by Box Behnken response surface design	156
6A.3.2	<i>In vitro</i> characterization of optimized VPN-PNP	168
6A.3.2.1	Shape and surface morphology	168
6A.3.2.2	Zeta potential	170
6A.3.2.3	<i>In vitro</i> drug release study	170
<b>Chapter 6B: Formulation Development: Polymeric Nanoparticles of Noopept</b>		<b>173-202</b>
6B.1.	Introduction	173
6B.2.	Materials & methods	173
6B.2.1	Materials	173
6B.2.2	Preparation of Noopept loaded polymeric nanoparticles (NPT-PNP)	174
6B.2.2.1	Establishing Quality target product profile (QTPP) and Critical Quality Attributes (CQA)	174
6B.2.2.2	Identification of Independent variables (factors) and qualitative risk assessment	174
6B.2.2.3	Quantitative risk assessment: Screening design	175
6B.2.2.4	Formulation optimization by Box Behnken response surface design	176
6B.2.3	<i>In vitro</i> characterization of optimized NPT-PNP	176
6B.2.3.1	Shape and surface morphology	176
6B.2.3.2	Zeta potential	177
6B.2.3.3	<i>In vitro</i> drug release study	177
6B.3.	Results & discussion	177
6B.3.1	Preparation and optimization of NPT loaded polymeric nanoparticles	177
6B.3.1.1	Establishing QTPP and CQA	177
6B.3.1.2	Identification and qualitative assessment of Independent variables (factors)	178
6B.3.1.3	Qualitative risk assessment	179
6B.3.1.4	Quantitative risk assessment: Screening Design	181
6B.3.1.5	Formulation optimization by Box Behnken response surface design	184
6B.3.2	<i>In vitro</i> characterization of optimized NPT-PNP	197
6B.3.2.1	Shape and surface morphology	197
6B.3.2.2	Zeta potential	199
6B.3.2.3	<i>In vitro</i> drug release study	199
<b>Chapter 7: Formulation Development: Fast Dissolving Microneedle Patch</b>		<b>203-230</b>
7.1.	Introduction	203
7.2.	Materials & methods	204
7.2.1	Materials	204
7.2.2	Preparation of poly-dimethylsiloxane (PDMS) micromolds	204

<b>Section</b>	<b>Description</b>	<b>Pg. No.</b>
7.2.3	Preparation of fast dissolving microneedle patch	205
7.2.3.1	Establishing Quality target product profile and Critical Quality Attributes	205
7.2.3.2	Identification of Independent variables (factors) and qualitative risk assessment	205
7.2.3.3	Formulation optimization by combined D-optimal response surface design	206
7.2.4	<i>In vitro</i> characterization of fast dissolving MNP	207
7.2.4.1	Shape and surface morphology	207
7.2.4.2	Skin penetrability	207
7.2.4.3	Pore closure study	207
7.2.5	Preparation of nanocarriers loaded fast dissolving MNP	207
7.2.6	<i>In vitro</i> characterization of nanocarriers loaded fast dissolving MNP	208
7.2.6.1	Shape and surface morphology	208
7.2.6.2	Axial needle fracture force measurement	208
7.2.6.3	<i>In vitro</i> dissolution time	208
7.2.6.4	Physical stability of nanocarriers in fast dissolving MNP	208
7.2.6.5	<i>In vitro</i> drug release	208
7.3.	Results & discussion	209
7.3.1	Preparation of PDMS micromolds	209
7.3.2	Preparation and optimization of fast dissolving MNP	209
7.3.2.1	Establishing QTPP and CQA	209
7.3.2.2	Identification and qualitative assessment of Independent variables (factors)	211
7.3.2.3	Qualitative risk assessment	212
7.3.2.4	Formulation optimization by combined D-optimal response surface design	214
7.3.3	<i>In vitro</i> characterization of fast dissolving MNP	220
7.3.3.1	Shape and surface morphology of MNP	221
7.3.3.2	Skin penetrability	222
7.3.3.3	Pore closure study	222
7.3.4	Preparation of nanocarriers loaded fast dissolving MNP	224
7.3.5	<i>In vitro</i> characterization of nanocarriers loaded fast dissolving MNP	224
7.3.5.1	Shape and surface morphology of MNP	224
7.3.5.2	Axial needle fracture force measurement	225
7.3.5.3	<i>In vitro</i> dissolution time	226
7.3.5.4	Physical stability of nanocarriers in fast dissolving MNP	226
7.3.5.5	<i>In vitro</i> drug release	227

Section	Description	Pg. No.
<b>Chapter 8: Safety &amp; <i>Ex vivo</i> Permeability Studies</b>		<b>231-246</b>
8.1.	Introduction	231
8.2.	Materials & methods	231
8.2.1	Materials	231
8.2.2	Reagents	232
8.2.2.1	Povidone-Iodine solution	232
8.2.2.2	Phosphate buffer saline, pH 7.4 (PBS 7.4)	232
8.2.2.3	Glycerol solution in PBS 7.4 (Gly-PBS 7.4)	232
8.2.2.4	Growth media	232
8.2.2.5	Treatment media	232
8.2.2.6	MTT solution	233
8.2.3	Skin procurement and preservation	233
8.2.4	<i>Ex vivo</i> Permeation and deposition study	233
8.2.5	<i>Ex vivo</i> fluorescence microscopy study	234
8.2.6	<i>In vitro</i> cell viability study	235
8.2.6.1	Cell culture handling and Sub-culturing	235
8.2.6.2	MTT assay	235
8.3.	Results & discussion	236
8.3.1	<i>Ex vivo</i> permeation and deposition of VPN	236
8.3.2	<i>Ex vivo</i> fluorescence microscopy study	240
8.3.3	<i>In vitro</i> cell viability evaluation	243
<b>Chapter 9: <i>In vivo</i> Studies</b>		<b>247-262</b>
9.1	Introduction	247
9.2	Methods	247
9.2.1	Study protocol authorization	247
9.2.2	Animal procurement	248
9.2.3	Animal equivalent dose calculation	248
9.2.4	Pharmacokinetic study of VPN	249
9.2.5	Pharmacokinetic study of NPT	250
9.2.6	Pharmacodynamic study of VPN	251
9.2.6.1	Spatial Learning performance using Morris Water Maze test	251
9.2.7	Pharmacodynamic study of NPT	252
9.3	Results & discussion	253
9.3.1	Pharmacokinetic study of VPN	253
9.3.2	Pharmacokinetic study of NPT	255
9.3.3	Pharmacodynamic study of VPN	257
9.3.4	Pharmacodynamic study of NPT	260

<b>Section</b>	<b>Description</b>	<b>Pg. No.</b>
9.4	Conclusion	261
<b>Chapter 10: Stability Study</b>		<b>263-266</b>
10.1.	Introduction	263
10.2.	Materials & Methods	263
10.2.1	Materials	263
10.2.2	Short term stability study of nanocarriers loaded MNP	263
10.3.	Results & discussion	264
10.3.1	Short term stability study	264
<b>Chapter 11: Summary &amp; Conclusion</b>		<b>267-282</b>
11.1	Introduction	267
11.1.1	Aims of the study	270
11.2	Analytical method development	270
11.3	Preformulation studies	271
11.4	VPN and NPT loaded UDL	272
11.5	VPN and NPT loaded PNP	274
11.6	UDL and PNP loaded fast dissolving MNP	277
11.7	Safety and permeability evaluation	279
11.8	<i>In vivo</i> studies	280
11.9	Stability study	281
11.10	Conclusion	281
11.11	Future perspective of present study	282